Dr. Mou has 20 Years of industrial experience in CMC development and commercial manufacturing, quality, supply chain，global operation, and new business establishment starting from 0 to 600 people. She currently serves as an expert at IFPMA for the new Cell and Gene Therapies Discussion Group (CGTDG), and a member at Drug R&D Specialty Committee of PHIRDA. Dr. Mou is experienced in mAb, ADC, mRNA, VLP, AdV, AAV in therapeutic and preventive treatments, vaccine, CGT, rare diseases. She served as the Vice President in WuXi Biologics Development and Manufacturing and the Site Head of Hangzhou, China; worked on drug development in Pfizer’s BioTherapeutics division (US) and in Merck (MSD US); Dr. Mou obtained her Ph.D. in Chemical Biology from Rensselaer Polytechnic Institute (RPI), and B.S. in Chemistry from Fudan University, China.